Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 3 1

Status

Recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Classical hematology 2

Conditions

Venous Thrombosis 2Venous Thromboembolism 2Pulmonary Embolism 2Thrombosis 1Thromboembolism 1Thrombocytopenia 1Neoplasms 1

Interventions

Specimen Handling 613pembrolizumab 563Magnetic Resonance Spectroscopy 536Carboplatin 425Cisplatin 375Cyclophosphamide 373Biopsy 357Paclitaxel 306Gemcitabine 303Nivolumab 300Radiotherapy 260Bevacizumab 234Dexamethasone 209fludarabine 205Docetaxel 187durvalumab 182atezolizumab 173Oxaliplatin 172venetoclax 168Fluorouracil 166Rituximab 165Pemetrexed 163Capecitabine 158Doxorubicin 157Radiation 155Radiosurgery 148Etoposide 137Leucovorin 133Ipilimumab 133Lenalidomide 131

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × apixaban × 90 days × Clear all
NCT07493304 2026-05-29

ROXI-CAT-II

Regeneron Pharmaceuticals

Phase 3 Recruiting
1,600 enrolled
Classical hematology

Neoplasms, Pulmonary Embolism, Venous Thrombosis, Venous Thromboembolism

NCT06886516 2026-04-15

Apixaban in Thrombocytopenia

Beth Israel Deaconess Medical Center

Phase EARLY_PHASE1 Recruiting
30 enrolled
Classical hematology

Pulmonary Embolism, Thrombocytopenia, Thromboembolism, Thrombosis, Venous Thrombosis, Venous Thromboembolism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡